Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | NEK2 | P51955 | 1/20 | 0.48 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 3/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439601 | 0.88 | CHEK1 (0.53) | CA2CHEK1NEK2LIMK1DYRK1A | |
| SCHEMBL8720110 | 0.82 | CHEK1 (0.65) | CA2CHEK1NEK2LIMK1DYRK1A | |
| SCHEMBL1201242 | 0.78 | ALDH1A1 (0.46) | CA2CHEK1NEK2LIMK1DYRK1A | |
| SCHEMBL29987688 | 0.78 | ALDH1A1 (0.46) | CA2CHEK1NEK2LIMK1DYRK1A | |
| Hydrochloric Acid SCHEMBL2870378 | 0.76 | ALDH1A1 (0.44) | CA2CHEK1NEK2LIMK1DYRK1A | |
| SCHEMBL13845098 | 0.74 | ALDH1A1 (0.59) | CA2CHEK1NEK2LIMK1DYRK1A | |
| SCHEMBL24627048 | 0.73 | MAPT (0.65) | CA2CYP1A2TDP1L3MBTL1F2 | |
| SCHEMBL25721776 | 0.72 | KDM4E (0.39) | CA2CHEK1NEK2LIMK1DYRK1A | |
| SCHEMBL25711790 | 0.72 | KDM4E (0.35) | CA2CHEK1NEK2LIMK1DYRK1A | |
| SCHEMBL8990307 | 0.71 | CHEK1 (0.73) | CA2CHEK1NEK2LIMK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-20240023428-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL, ELECTRONIC ELEMENT, AND ELECTRONIC DEVICE | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-10-05 | — | — | US | disclosed |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-08-08 | — | — | US | disclosed |
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 2022-12-08 | — | — | US | disclosed |
| US-20210317097-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2021-10-14 | — | — | US | disclosed |
| WO-2021035101-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-02-25 | — | — | WO | disclosed |
| US-9862680-B2 | Peripherally substituted monocyclic beta-lactams | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170355671-A1 | PERIPHERALLY SUBSTITUTED MONOCYCLIC BETA-LACTAMS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355671-A1 | PERIPHERALLY SUBSTITUTED MONOCYCLIC BETA-LACTAMS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20140037693-A1 | 6\"-AMINO-6\"-DEOXYGALACTOSYLCERAMIDES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-02-06 | — | — | US | disclosed |
| US-20130158063-A1 | Compounds, Compositions and Methods Related to PPAR Antagonists | GEORGETOWN UNIVERSITY (US) | 2013-06-20 | — | — | US | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8445272-B2 | Method of stimulating NKT with 6″-amino-6″-deoxygalactosylceramides | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120028915-A1 | 6\"-AMINO-6\"-DEOXYGALACTOSYLCERAMIDES | THE SCRIPPS RESEACH INSTITUTE (US) | 2012-02-02 | — | — | US | disclosed |
| US-7989423-B2 | 6″-amino-6″-deoxygalactosylceramides | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100137231-A1 | 6\"-AMINO-6\"-DEOXYGALACTOSYLCERAMIDES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-06-03 | — | — | US | disclosed |
| US-7645873-B2 | 6-azido-2,3,4-tetra-O-benzyl-6-deoxymethylgalactopyranoside ; for treating cancer or autoimmune disorders | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-01-12 | — | — | US | disclosed |
| US-7288571-B2 | Thyroid receptor ligands and method II | KARO BIO AB (SE) | 2007-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355671-A1 | PERIPHERALLY SUBSTITUTED MONOCYCLIC BETA-LACTAMS | GNE, BPGM, MGAM | CA2 4545/4885CHEK1 2541/4885NEK2 2507/4885 |
| US-20130158063-A1 | Compounds, Compositions and Methods Related to PPAR Antagonists | PPARG, PPARA, PPARD | CA2 3790/4885CHEK1 2056/4885NEK2 1150/4885 |
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | TARDBP, TDP1, TDP2 | CA2 4174/4885CHEK1 2614/4885NEK2 3338/4885 |
| US-20100137231-A1 | 6\"-AMINO-6\"-DEOXYGALACTOSYLCERAMIDES | FUT6, GALNT6, ST6GAL1 | CA2 1060/4885CHEK1 4258/4885NEK2 4409/4885 |
| US-20210317097-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | CA2 4223/4885CHEK1 639/4885NEK2 459/4885 |
| US-20120028915-A1 | 6\"-AMINO-6\"-DEOXYGALACTOSYLCERAMIDES | FUT6, GALNT6, ST6GAL1 | CA2 1060/4885CHEK1 4258/4885NEK2 4409/4885 |
| US-20240023428-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL, ELECTRONIC ELEMENT, AND ELECTRONIC DEVICE | L1CAM, EPCAM, SELE | CA2 2500/4885CHEK1 3325/4885NEK2 1219/4885 |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | CA2 4223/4885CHEK1 639/4885NEK2 459/4885 |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | MAPK1, MAPK8, MAPK4 | CA2 4223/4885CHEK1 639/4885NEK2 459/4885 |
| US-20140037693-A1 | 6\"-AMINO-6\"-DEOXYGALACTOSYLCERAMIDES | FUT6, GALNT6, ST6GAL1 | CA2 1060/4885CHEK1 4258/4885NEK2 4409/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | CA2 71/4885CHEK1 4354/4885NEK2 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.